<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10027342</article-id><article-id pub-id-type="pmc">2362432</article-id><article-id pub-id-type="pii">6690100</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690100</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Role of dexamethasone dosage in combination with 5-HT<sub>3</sub> antagonists for prophylaxis of acute chemotherapy-induced nausea and vomiting</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>M&#x000fc;nstedt</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>M&#x000fc;ller</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Blauth-Eckmeyer</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Stenger</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zygmunt</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vahrson</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1">Department of Gynecological Oncology and Radiotherapy, Justus-Liebig-University Giessen, Klinikstrasse 32, Giessen, D 35392, Germany</aff><aff id="aff2">Synthelabo Arzneimittel, Lindberghstrasse 1, Puchheim, 82178, Germany</aff></contrib-group><pub-date pub-type="ppub"><month>2</month><year>1999</year></pub-date><volume>79</volume><issue>3-4</issue><fpage>637</fpage><lpage>639</lpage><history><date date-type="received"><day>04</day><month>02</month><year>1998</year></date><date date-type="rev-recd"><day>29</day><month>05</month><year>1998</year></date><date date-type="accepted"><day>09</day><month>06</month><year>1998</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 1999 Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Dexamethasone (20 mg) or its equivalent in combination with 5-HT<sub>3</sub> antagonists appears to be the gold-standard dose for antiemetic prophylaxis. Additional to concerns about the use of corticosteroids with respect to enhanced tumour growth or impaired killing of the tumour cells, there is evidence that high-dosage dexamethasone impairs the control of delayed nausea and emesis, whereas lower doses appear more beneficial. To come closer to the most adequate dose, we started a prospective, single-blind, randomized trial investigating additional dosage of 8 or 20 mg dexamethasone to tropisetron (Navoban), a 5-HT<sub>3</sub> receptor antagonist, in <italic>cis</italic>-platinum-containing chemotherapy. After an interim analysis of 121 courses of chemotherapy in 69 patients, we have been unable to detect major differences between both treatment alternatives. High-dose dexamethasone (20 mg) had no advantage over medium-dose dexamethasone with respect to objective and subjective parameters of acute and delayed nausea and vomiting. In relation to concerns about the use of corticosteroids in non-haematological cancer chemotherapy, we suggest that 8 mg or its equivalent should be used in combination with 5-HT<sub>3</sub> antagonists until further research proves otherwise. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>nausea</kwd><kwd>emesis</kwd><kwd>vomiting</kwd><kwd>corticosteroid</kwd><kwd>dexamethasone</kwd></kwd-group></article-meta></front></article>